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Abstract
Background: RECQL is a DNA helicase involved in DNA mismatch repair. The RECQL polymorphism,
3` untranslated region (UTR) A159C, was previously associated with overall survival of patients with
resectable pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. In the present study, we
examined RECQL for somatic mutations and other polymorphisms and compared these findings with the
outcome in patients who received adjuvant or neoadjuvant chemoradiation. We hypothesized that RECQL
(i) would be mutated in cancer, (ii) would have polymorphisms linked to the 3`UTR A159C and that either
or both events would affect function. We also hypothesized that (iii) these changes would be associated
with survival in both cohorts of patients.
Material and methods: We sequenced RECQL's 15 exons and surrounding sequences in paired blood
and tumour DNA of 39 patients. The 3`UTR A159C genotype was determined in blood DNA samples from
176 patients with resectable pancreatic adenocarcinoma treated with adjuvant (53) or neoadjuvant (123)
chemoradiation. Survival was calculated using the Kaplan–Meier method, with log rank comparisons
between groups. The relative impact of genotype on time to overall survival was performed using the Cox
proportional hazards model.
Results: Somatic mutations were found in UTRs and intronic regions but not in exonic coding regions
of the RECQL gene. Two single nucleotide polymorphisms (SNPs), located in introns 2 and 11, were found
to be part of the same haplotype block as the RECQL A159C SNP and showed a similar association with
overall survival. No short-term difference in survival between treatment strategies was found. We iden-
tified a subgroup of patients responsive to neoadjuvant therapy in which the 159 A allele conferred
strikingly improved long-term survival.
Discussion: The RECQL 3`UTR A159C SNP is not linked with other functional SNPs within RECQL but
may function as a site for regulatory molecules. The mechanism of action needs to be clarified further.
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Introduction
With an estimated 37 680 new diagnoses and 34 290 deaths in
2008, cancer of the pancreas is the eleventh most common
cancer in the United States and fourth in fatalities.1,2 Most
American centres treat resectable pancreatic cancer with resec-
tion followed by adjuvant chemoradiation, which extends sur-
vival from 12 months with surgery alone to about 20 months
with adjuvant chemoradiation, with a 20% 5 year post-operative
survival. Conversely, the neoadjuvant approach, with assured
administration of chemoradiation to all potential surgical
candidates and potentially improved patient tolerance prior
to surgery, offers some theoretical advantages over immediate
surgery. Pre-operative treatment may decrease tumour size and
increase the chances of an R0 (microscopically negative margin)
resection. However, about 30% of patients treated with pre-
operative chemoradiation will develop progressive disease and
will never come to surgery. Clearly, discovery of a means to
predict the outcome with the adjuvant or neoadjuvant approach
would be extremely useful.
Gemcitabine (GEM) is the standard chemotherapy for
pancreatic cancer. GEM interferes with DNA replication and
prevents the proofreading enzymes from detecting, excising and
repairing the DNA.3 In vitro studies have shown that cells defi-
cient in DNA mismatch repair (MMR) enzymes are more sen-
sitive to GEM/radiation.4 The RecQ family is a highly conserved
group of DNA helicases required for the maintenance of genome
stability and integrity. They have an important role in DNA
replication, telomere maintenance, DNA damage signalling and
DNA repair pathways including mismatch repair, nucleotide
excision repair and direct repair.5,6 The most highly expressed
but smallest member of this family in human cells is the RecQ
protein-like (DNA helicase Q1-like) (RECQL often named
RECQ1). RECQL catalytic activities include the DNA unwinding
of diverse but specific DNA structures, the annealing of comple-
mentary single-stranded DNA and DNA branch migration.7–11
This protein plays an important role in chromosomal stability
and genome maintenance.11 It interacts with and binds to mis-
match repair proteins that regulate genetic recombination12 and
participates in the repair of endogenous or exogenously induced
DNA damage.13 RECQL is highly expressed in rapidly proli-
ferating cancer cells and transformed cells and provides these
cells with a growth advantage14,15 suggesting that greater copy
numbers of RECQL may be needed to repair the elevated load
of endogenous DNA damage generated during their accelerated
cell cycle. Accordingly, RECQL acute depletion (silencing by
small interference RNA) in cancer cells induces growth retar-
dation, sensitivity to DNA damaging agents, accumulation of
DNA damage, chromosomal instability and ultimately results
in mitotic catastrophe coupled with mitotic cell death in cancer
cells already compromised in their checkpoint.12,15 Conversely,
allelic loss at the RECQL locus (chromosome 12p12) is frequent
in different tumour types.11
Alteration in DNA repair pathways may affect the cytotoxicity
of chemotherapy and radiotherapy, more specifically the resis-
tance to gemcitabine-induced DNA replication arrest and the
repair of DNA double-strand breaks caused by radiation. The
importance of RECQL in damage repair is further supported
by the observation that a single nucleotide polymorphism (SNP)
located in the 3′ untranslated region (UTR) (A159C) negatively
affects the overall survival and response to gemcitabine-induced
radiosensitization of patients diagnosed with pancreatic adeno-
carcinoma treated with neoadjuvant chemoradiation.16,17 This
SNP exerts its effect in a dominant-inheritance mode.
Genetic changes can be considered either germline or somatic.
Germline variation refers to an alteration in DNA sequence inher-
ited from one’s parents. Single nucleotide polymorphisms (SNPs)
account for more than 90% of germline variation in the human
genome, and have been implicated in phenotype, disease predis-
position and response to therapy.18,19 Somatic mutations, to the
contrary, are found in diseased tissue (i.e. tumour) only, and
are not a part of the inherited genetic complement. By altering
protein function, somatic mutations can have a profound impact
on tumour development and proliferation (e.g. tumour sup-
pressor genes and oncogenes).
In the present study, the RECQL gene was sequenced in patients
with pancreatic cancer to discover the presence of additional SNPs
or mutations in the coding region that may directly affect the
function of the gene. In addition, to evaluate the prognostic value
of the 3′UTR A159C SNP in association with the course of treat-
ment, the effect of the SNP on clinical outcome was compared
in two cohorts of patients with resectable pancreatic cancer:
one treated with resection and adjuvant chemoradiation, and the
other treated with neoadjuvant chemoradiation with surgery or
additional chemotherapy as indicated by repeat CT scan.
Material and methods
Sample collection and processing
Informed consent from patients with resectable pancreatic exo-
crine adenocarcinoma was obtained under an institutional review
board approved protocol at the institutions participating in this
study (BCM: H16215 issued 9/22/04; TJU: 06U.76 issued 4/27/06;
MDA: ID 98–155 issued 09/09/98). A total of 53 patients with
exocrine adenocarcinoma located in the head of the pancreas were
treated with pancreaticoduodenectomy (Whipple procedure) and
adjuvant chemoradiation at the Elkins Pancreas Center at Baylor
College of Medicine (BCM), Houston, and the Thomas Jefferson
University Center (TJU) for Pancreatic, Biliary and Related
Cancers, Philadelphia (26 and 27 patients, respectively). One
hundred twenty-three patients received neoadjuvant chemora-
diation at the University of Texas MD Anderson Cancer Center
(MDACC).
The blood from the BCM patients was directly collected in
PAXgene Blood DNA tubes, and the DNA was isolated with the
PAXgene Blood DNA kit (PreAnalytiX; Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions. The MDACC
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blood samples were collected in heparinized vacutainers (BD
Biosciences, Franklin Lakes, NJ, USA), and the peripheral mono-
nuclear cells were immediately separated by Ficoll-Histopaque
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) density gra-
dient centrifugation; the DNA was then extracted with the Flexi-
Gene DNA kit (Qiagen). At TJU, after surgical resection, genomic
DNA was isolated from normal and tumour pancreatic tissue.
gDNA was extracted using the DNeasy Blood and Tissue Kit
(Qiagen).
Sequencing data were obtained from 39 macroscopically
dissected pancreatic adenocarcinoma tissue specimens from
operative cases (head, tail and metastasizing tumours) and match-
ing blood from the same patient (BCM). The tissue samples were
stored in a protease inhibitor solution (Roche Applied Science,
Indianapolis, IN, USA) at -80°C.19,20 The DNA was isolated from
the preserved tissue using the QIAamp DNA Mini kit (Qiagen)
after washing the tissue several times in phosphate-buffered saline
(PBS) to remove any trace of the stabilizing solution.
Gene amplification and sequencing
The exons and their flanking sequences (300 bases) of RECQL
were identified using the UCSC genome bioinformatics website
(http://genome.ucsc.edu; accessed 18 June 2009). Primer sets
(Table 1) were designed using the HGSC primer design pipeline
that links several software in an integrated automatic approach as
previously described.19
Ten to fifty nanograms (ng) of DNA was whole genome ampli-
fied (WGA) (GenomiPhi DNA amplification kit, Amersham
Biosciences). PCR was performed on 10 ng of WGA DNA in a final
reaction volume of 8 ml in a 384-well plate using the HotStar
polymerase (Qiagen). Cycling parameters consisted of 40 cycles of
a denaturation step at 95°C for 45 s followed by an annealing step at
60°C for 45 s, and an extension step at 72°C for 45 s. The cycling
process was preceded by a denaturation period at 95°C for 15 min
and followed by a final extension period of 7 min at 72°C. Un-
consumed dNTPs were hydrolyzed and remaining primers were
degraded using a cocktail of Shrimp Alkaline Phosphatase and
Table 1 Primer sets and probes used for sequencing, validation and genotyping
Sanger sequencing primer sets
Exon Forward primer Forward primer
1 TAACTTTCCGGTTTCTCCTCCG TTCCTATTGGCGAAACCTGCTT
1 TGGAGGAAACGCCACTGAGATA AGCTTTGAAGGGTCAAGGGTGT
2 CAAACAGAAATAGAACAGAAGGAAGAAGA TGGTTCTTATTTGAAAGGTCACTGC
3 CTGCAAGTTTCCCATTCCACTG CTGTAATTGATATGGCGGGCAA
4 TGACAAAGCACTTCTTCAACTCAAA TTTGCTTTGCTTAGCTAGTGAGT
5 GCAGGTAAAGCTCCTATTTCAGTG GCATCTGATTCTGAGGGTGGTG
6 AGCAGAGATTTCCATCATGCCA TGCTCCTAGAAGAGCCAAAGGC
7 CCCTCTGCGTAATTCTTCACAAA CCTGCCCATCAAAGAGGCTAAC
8 TCTCTGTCTCCAAAGTTGGTTTG TCTGGGAGGAGGAACAGATGAG
9 TCAATTCCCATACCAAATGCAA CAATGTCCTGAATGTGTGTGTTGA
10 CCATATGCAAGTAAGTGTCAAACTGC TGCTTACCATGCCAATTTGGAG
11 GATGTGCTGGTTCCTACCCTCC GGGTACCCATTACAAATTAACTTCCAC
12 CACTAGGCATTATGACTGTATTAGCC ATCCAGTGAAACCCATAGTACACTTC
13 AAACCGTTTATTCTGTTGCAATTT AGGGTGGCTCACATTGATAACC
14 CAATGTGTTAAGAATTACTGCGCATA GAAAAGCATCCCATAGGCTTT
15 AAACTTAAGACGATTGTATGAACTTATTCTC TTTGTAGGCTGAATCGTCTCAAAC
15 AAACTTAAGACGATTGTATGAACTTATTCTC GAAAAGAAAAATCGATGATGCCT
15 CACTCAGTGAACCTCTGTCAGT TTTGAGAATAAGTTCATACAATCGTC
Biotage primer set
SNP Forward primer Reverse primer Sequencing primer
Intron 2, IVS2 - 17 TTTCCGTAAGTTCTTGAATTTG TCAATCTGGAAACCTAAAGTTGTA CTATGGGAGGCAGCG
intron 11, IVS11 + 30 GGGCATCTTTTCTTGAACTAAGG GCAGAAGCTTTATGAGATGGTATC CTTTCATATTTGCTTTAATT
3` UTR, A159C AATAATGGCATATACATGCATAAA ACAGGAGCTAAGAAAAGAAAAATC TCGATGATGCCTGATA
TaqMan primer and probe set
SNP Forward primer Reverse primer Probe
3` UTR, A159C CAATCTGGTTCTAAGAATACAGGAGCTA GGCATATACATGCATAAACCATCTTT AGTAACAGTCATATCAGG
AGTAACATTCATATCAGGC
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Exonuclease I (ExoSAP-IT, USB). The purified PCR products were
diluted and sequenced using BigDye Terminator version 3.1
Cycle Sequencing kit on Applied Biosystems (Foster City, CA, USA)
3730XL DNA Sequencers. The sequences were analysed with SNP
Detector version 3 (created by Jinhui Zhang et al.21 at the NCI)
using the corresponding sequence deposited in GenBank as refer-
ence. Base disparities from the reference sequence identified by the
SNP Detector software were manually verified in Sequencher
version 4.6 (Gene Codes Corp). Somatic variants were identified by
comparing the sequences from each patient’s matched blood and
tumour samples.
Validation and genotyping
We validated the selected candidate variants by Biotage pyrose-
quencing. Briefly, Biotage assay design software was used to select
new PCR primers at each locus of interest, avoiding all known
SNPs and project-specific variants (Table 1). One of each primer
pair was tailed with a 23 base extension corresponding to the
sequence of a biotinylated universal primer. Primers successfully
tested for amplification product on human cell line DNA were
combined with the universal primer and used to amplify patient
DNA samples. Each amplicon was reduced to single strand by
denaturation and binding to streptavidin beads. Sequence-specific
extension primers were annealed within four bases of the target
variant and extended using the standard Biotage pyrosequencing
protocol and reagents. The resulting 8 to 15 bases of sequence
were analysed for quality based on pyrogram peak geometry and
genotype using Biotage software algorithms.
The 3′UTR A159C SNP was also genotyped with the TaqMan
SNP Genotyping assay (Applied Biosystems) (Table 1). The reac-
tions were prepared using 10 ng of gDNA, TaqMan universal
master mix and SNP genotyping assay mix in a final volume of
5 ml. The PCR was done using the ABI Prism 7900 HT sequence-
detector.
Statistical methods
Estimations of survival were performed via the Kaplan–Meier
method, with comparisons in survival between groups made pair-
wise by log-rank tests. Differences in distribution of variables
between groups were calculated using Pearson’s c2-test. Potential
confounders were identified by univariate analysis; individual
variable’s relative effect on survival was estimated via a Cox
regression model. All statistical calculations were performed with
SPSS version 12.0.1 (SPSS Inc., Chicago, Illinois, USA).
Results
Sequencing results: somatic events (specifically
found in tumour DNA only)
We sequenced the 15 exons and surrounding intronic regions
of the RECQL gene in 39 matched blood and tumour samples of
patients diagnosed with pancreatic adenocarcinoma resected
before chemoradiation. A total of 26 events were identified
(Table 2). Out of these events, two consisted of a somatic base shift
mutation located in the 5′UTR, and intron 1 in two patient
tumours (Tables 2,3). Six other somatic events located in five
different introns as well as the 3′UTR A159C consisted of loss of
heterozygocity (LOH) at the site of known polymorphisms. Most
of these somatic events were found in two patients (Tables 2,3).
Sequencing results: germline polymorphisms (found
in blood as well as tumour DNA)
The remaining events consisted of 24 polymorphisms, of which15
were known to be present in the general population, and had an
assigned ID number (http://genewindow.nci.nih.gov; accessed 18
June 2009). Fourteen SNPs (nine known) were located in the
intronic region outside the splicing site, six SNPs (three known) in
the UTRs of the gene, one known SNP 115 bases upstream of exon
1, and three SNPs in the coding region of exon 13 (unknown
missense SNP), exons 14, and 15 (both silent known SNPs)
(Table 3). The impact of the missense mutation on recql function
was suggested to be benign based on a PolyPhen analysis (http://
genetics.bwh.harvard.edu/pph/; accessed 18 June 2009).
Nine SNPs were part of three haplotype blocks (Table 3): hap-
lotype 1: IVS2 - 17, IVS11 30, Ex15 + 159 (3′ UTR A159C);
haplotype 2: IVS7 - 69, IVS8 - 33, IVS10 + 82, and IVS11 + 103;
and haplotype 3: Ex14 + 64 and Ex15 + 102. First we genotyped
eight of the SNPs showing greater heterozygocity in DNA
extracted from the blood of 77 patients receiving neoadjuvant
therapy. Only three SNPs had any correlation with overall sur-
vival: they were part of the first haplotype block described above.
The total number of genotyped patients was then increased to
123 and the overall survival curves by genotype were established
for each SNP. From the three SNPs, the 3′UTR A159C was the
most statistically significant (Fig. 1).
Table 2 RECQL germline and somatic events identified in blood and matching tumour of patients with pancreatic exocrine adenocarcinoma
Gene region Total event Germline SNP Somatic
LOH Base shift
Promoter 1 1
Intron 15 14 5 1
Exon: UTR 7 6 1 1
Coding: synonymous 2 2
Coding: nonsynonymous 1 1
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The 3`UTR A159C polymorphism: correlation between
survival and course of treatment
We compared the influence of the 3′UTR A159C SNP on overall
survival between patients treated with neoadjuvant chemo-
radiation and adjuvant therapy. Characteristics of the two
cohorts of patients are detailed in Table 4. The two groups
were similar in age, race, pre-operative CA 19-9 and TNM
stage. There was no difference in overall survival between the
two groups (Fig. 2). Although there were differences in gender,
the number who underwent resection, tumour size and nodal
status, only negative nodal involvement offered a survival
advantage using Cox regression (HR 0.420, CI 0.233–0.760,
P = 0.004).
We determined the germline genotype from the blood DNA
of 123 patients receiving neoadjuvant therapy and 53 patients
receiving adjuvant therapy. No significant difference was
observed in the genotype distribution among the two groups:
the frequency of the A allele was 56.6% vs. 58.1%, respectively
(Table 5). No statistically significant difference in short-term sur-
vival was observed when comparing patients treated by the neo-
adjuvant vs. adjuvant approach within each respective genotype
(Table 6). For example, in comparing neoadjuvant and adjuvant
therapy in patients with the AA genotype, survival was 82% vs.
75% in the 1st year and 59% vs. 45% for the 2nd year. This
represented no significant difference between the two treatment
cohorts.
When comparing the effect of genotype within treatment
groups, patients with the AA genotype receiving neoadjuvant
chemoradiation were observed to have improved long-term sur-
vival compared with their AC and CC counterparts (Fig. 1,
Table 6). Five-year survival was 39% for AA patients, compared
with 14% for genotype AC, (P = 0.025) and 19% for genotype CC
(P = 0.003). The AA genotype was an independent predictor of
improved survival by Cox regression (HR 2.51, CI 1.321–4.756,
P = 0.005). No long-term survival data were available for the
patients receiving adjuvant chemoradiation. However, no statis-
tically significant difference in short-term survival by genotype
was seen after 30 months.
We further analysed the population that received neoadjuvant
therapy by dividing these patients into two groups based on resec-
tability after chemoradiation.A survival benefit was again observed
with the AA genotype in those undergoing surgical resection after
chemoradiation, with survival of 97%, 80%, and 55% at 1, 2 and
5 years, respectively vs. 89%, 62%, and 19% for AC patients (P =
0.010), and 93%, 36%, and 29% for CC patients (P = 0.003) (Fig. 3,
Table 7). The AA genotype was again a predictor of survival (HR
2.92, CI 1.531–5.564, P = 0.001). However, none of the genotypes
conferred a survival benefit in patients that could not undergo
resection as a result of progressive disease during neoadjuvant
chemoradiation (Fig. 3). These patients had a 2-year survival of
10% for all genotypes.The difference in survival was highly empha-
sized when the outcomes of each genotype were compared (Fig. 4).
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Figure 1 Comparison of the overall survival by genotype of three single nucleotide polymorphisms (SNPs) from the same haplotype. The
genotypes CC, TT and AA at IVS32 - 17, IVS11 + 30, and at the base 159 of exon 15 in the 3` untranslated region (UTR) confer a similar
overall survival advantage to the 123 patients that received neoadjuvant therapy. The 3`UTR A159C has a greater statistical significance.
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Discussion
Although this study provided a more thorough sequencing of the
RECQL gene in the pancreatic cancer patient population, it failed
to identify mutations in the coding region of the gene that would
impair its functionality. Only a few patients harboured an LOH
at the gene locus as previously observed in other cancer types.11
In this study, two SNPs in introns 2 and 11 of the RECQL gene
were identified as being in linkage disequilibrium with 3′ UTR
A159C and had a similar effect on clinical outcome. Therefore, the
mechanism of the association is unlikely to be a SNP resulting
in amino acid substitution and subsequent structural and func-
tional defects in the translated RECQL protein. The RECQL poly-
morphism may represent a binding site for regulatory molecules
that affect gene expression. Also, the polymorphism may impact
GEM’s mechanism of action. Both of these hypotheses will
require further investigation.
The 3′UTR A159C SNP is present at different frequency among
different ethnicities as reported by the HapMap project and
other studies (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=
13035; 18 June 2009). The frequency of the A allele is about 55%
in the Asiatic population, 57% in the Caucasian and 90% in the
Yoruban population. The frequency of the AA genotype is as low
as 16% in some Asiatic ethnicities, about 35% in the Caucasian
population, and over 80% in the Yoruban population. We
observed a similar genotype distribution among our pancreatic
cancer patients.
The present study adds further information to the observation
that the well known and validated RECQL polymorphism, 3′UTR
A159C, is associated with overall survival of patients with resect-
able pancreatic adenocarcinoma. No significant difference in
short-term survival was observed by genotype between the patients
treated with neoadjuvant and adjuvant therapy. A key weakness of
this study is the small sample size and limited follow-up, particu-
larly in the group treated with adjuvant chemoradiation. Long-
term follow-up of these patients is necessary to see if trends in
survival similar to that seen in the neoadjuvant group develop.
Similar to previously reported series, 34% of patients treated
neoadjuvantly progressed to unresectable disease. The subset of
unresectable neoadjuvant patients in our population experienced
extremely poor clinical results, with most dying within a year of
diagnosis. Clearly, the genotype and other factors that determine
response to treatment and overall survival are multiple and
complex. Factors, including mutations in genes impacting tumour
behaviour or regulatory molecules, may be involved in worsening
patient survival in this subset. Chen et al. have also reported
polymorphisms in cell-cycle genes that had an impact on overall
survival in patients with resectable adenocarcinoma treated with
neoadjuvant chemotherapy.22 It is also possible that this subgroup
Table 4 Patient demographics
Neoadjuvant Adjuvant
123 patients 53 patients
Gendera Female 38.2% 58.5%
Male 61.8% 41.5%
Age group <50 12.2% 3.8%
51–60 22.8% 15.4%
61–70 38.2% 38.5%
>71 26.8% 42.3%
Race Caucasian 88.6% 81.1%
Hispanic 4.9% 3.8%
Black 4.9% 9.4%
Asian 1.6% 5.7%
CA 19-9 level <47 26% 26.8%
48–499 48% 39%
500–999 11.4% 12.2%
>999 14.6% 22.0%
Surgical resectiona Resected 65.9% 100%
Non-resectable 34.1% 0%
Tumour sizea <2 cm 42.2% 14.0%
>2 cm 57.6% 86.0%
TNM stage IA 7.8% 1.9%
IB 2.6% 3.8%
IIA 31.2% 21.2%
IIB 58.40% 73.10%
aSignificant difference between the two groups (P < 0.05).
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Figure 2 Cumulative overall survival of patients treated with adjuvant
and neoadjuvant therapy. No difference was noticed between the
two groups.
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of patients had already developed micrometastases that were
undetected at staging prior to the initiation of neoadjuvant
therapy.
Within the specific subgroup of patients responsive to neoad-
juvant therapy who proceeded to resection, the AA genotype
is associated with a relatively promising long-term survival,
making it a potentially good prognostic marker for this group.
However, the AA genotype was in equal prevalence in patients
who proceeded to resection as well as those who failed neoadju-
vant therapy. It does not appear, then, that the 3′UTR A159C
genotype can predict which patients will respond to neoadjuvant
chemoradiation. Thus, the clinical utility of this marker is limited
until a means of prospectively identifying this responsive sub-
group is established.
Conclusion
Recent advances in rapid DNA sequencing technology are
decreasing the cost and improving the efficiency of genetic
testing such that selection of therapy based on genetic analyses
of individual patients may soon become standard practice. This
personalized genomic approach to cancer therapy may improve
Table 5 RECQL A159C genotype distribution among the groups studied
Total AA AC CC % A allele
Adjuvant therapy
All patients 53 34.0% 45.3% 20.8% 56.6%
Neoadjuvant therapy
All patients 123 36.6% 43.1% 20.3% 58.1%
Resected 81 37.0% 45.7% 17.3% 59.9%
Unresected 42 35.7% 38.1% 26.2% 54.8%
Table 6 Survival comparison between the patients treated with neoadjuvant and adjuvant therapy
Genotype AA AC CC
Group Neoadjuvant Adjuvant Neoadjuvant Adjuvant Neoadjuvant Adjuvant
1 year 82% 75% 74% 70% 68% 45%
2 years 59% 45% 45% 52% 24% 34%
5 years 39% na 14% na 19% na
na, not available yet.
Figure 3 Comparison of the overall
survival by genotype between two sub-
groups of patients receiving neoadjuvant
therapy based on their resectability after
chemoradiation. Patients with the AA
genotype receiving the entire course of
treatment (chemoradiation and surgery)
had an impressive overall survival of
55% over 5 years. Conversely, no differ-
ence in overall survival was associated
with any genotype for patients unresec-
table after neoadjuvant therapy.
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results by selection of more beneficial treatments for each
patient and by avoiding the application of treatments that are
ineffective and toxic.23 In an era where the cost–benefit ratio of
treatments will be increasingly scrutinized, selection of patients
with pancreatic cancer, who have a universally fatal disease, that
would be likely to benefit from otherwise highly toxic and
expensive treatment modalities may become critical. The present
study retrospectively identified a distinct subset of pancreatic
cancer patients in whom a specific genotype was associated with
a nearly threefold increase in survival over that which is typically
reported in the literature. Current and future studies, including
whole-genome analysis of this population, may yield clinically
relevant data that can influence prospective medical decision
making and choice of therapy.
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